Cipla Agrimed (Pty) Ltd is the proprietor of South African Patent 92/7457 (1992 patent). Merck Sharp Dohme Corporation (first respondent) and Merial Limited (second respondent) are joint proprietors of South African Patent 98/10975 (1998 patent). Merial South Africa (Pty) Ltd (third respondent) is a registered licensee of the 1998 patent. Cipla brought a revocation application against the 1998 patent on grounds of anticipation and obviousness based on the 1992 patent. Merck instituted an infringement action against Cipla. The parties agreed to stay the infringement action pending the revocation application. In the revocation application, Cipla only argued the anticipation point. The Court of the Commissioner of Patents (Teffo J) upheld the anticipation point and granted revocation. On appeal, the Supreme Court of Appeal reversed this finding on 27 November 2015, dismissing the revocation application and certifying all claims of the 1998 patent as valid. Following this judgment, Merck demanded that Cipla consent to final relief in the infringement action. Cipla instead served notice to amend its plea to pursue the obviousness point (previously pleaded but not argued) and to add a new inutility point. Merck responded by alleging res judicata based on the SCA judgment. In January 2016, Merck launched an urgent application for an interim interdict pending final determination of the infringement action. Louw J granted the interim interdict on 4 March 2016, finding that validity was res judicata, and adding a proviso that the interdict would lapse on the patent expiry date (3 December 2018) if the action was not finally determined by then. Cipla appealed with leave.